Compositions and methods for treating cns disorders
AssigneeSage Therapeutics, Inc.
InventorsGabriel Martinez Botella, Francesco G. Salituro, Albert Jean Robichaud, Boyd L. Harrison
Life of this patent
Estimating the term…
Abstract
Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein , A, R1, R2, R3a, R4a, R4b, R5, R7a, and R7b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
Claims41
1-73. (canceled)
A compound of the Formula (I-a):
- or a pharmaceutically acceptable salt thereof;
- wherein:
- Ring A is a substituted heterocyclyl linked through a nitrogen atom or a substituted heteroaryl linked through a nitrogen atom;
- R1 is unsubstituted C1-3 alkyl, substituted C1-6 alkyl, haloalkyl, or alkoxyalkyl;
- R2 is hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 carbocylyl, or —ORA2, wherein RA2 is hydrogen or substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, or substituted or unsubstituted C3-6 carbocylyl;
- R3a is hydrogen or —ORA3, wherein RA3 is hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, or substituted or unsubstituted C3-6 carbocylyl, and R3b is hydrogen;
- or R3a and R3b are joined to form an oxo (═O) group;
- R4a is hydrogen, substituted or unsubstituted C1-6 alkyl, or —ORA4, wherein RA4 is hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, or substituted or unsubstituted C3-6 carbocylyl, and R4b is hydrogen or substituted or unsubstituted C1-6 alkyl;
- or R4a and R4b are joined to form an oxo (═O) group;
- or R4a and R4b together with the carbon atom to which they are attached form a ring;
- R5 is absent or hydrogen;
- Each R6 is substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 carbocylyl, C1-6 haloalkyl, halogen, cyano, —ORA6, —C(═O)ORA6, —SRB6, —S(═O)RB6, S(═O)2RB6, nitro, N(RC6)(RD6), C(═O)N(RC6)(RD6), or N(RC6)C(═O)RA6;
- wherein RA6 is hydrogen or substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 carbocylyl, or C1-6 haloalkyl;
- RB6 is substituted or unsubstituted C1-6 alkyl or substituted or unsubstituted C3-6 carbocylyl;
- and each of RC6 and RD6 is independently hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted carbocyclyl, or substituted or unsubstituted aryl, or RC6 and RD6 together with the nitrogen atom to which they are attached form a 3-6-membered substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl ring;
- n is 1, 2, or 3;
- each of R7a and R7b is independently hydrogen or halogen;
- is a single or double bond, wherein when one of is a double bond, the other is a single bond;
- and when one of the is a double bond, R5 and one of R7a and R7b is absent.
A compound selected from
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
A method of inducing sedation and/or anesthesia in a subject, comprising administering to the subject in need thereof an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
A method for treating seizure in a subject, comprising administering to the subject an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
A method for treating epilepsy or status or status epilepticus in a subject, comprising administering to the subject an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
A method for treating disorders related to GABA function in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.